Peer Reviewed Studies on Psilocybin.

Since 1997, when the first post-drug-war Psilocybin study was conducted by a team of researchers at the University of Zurich, interest in the substance by accredited & prestigious institutions has steadily increased.

 

Studies and early-phase clinical trials already concluded at John Hopkins University, The Multidisciplinary Association for Psychedelic Studies (MAPS), The Beckley Foundation, and New York University have shown promise for the safety and efficacy of psilocybin in treating a host of psychological conditions. Some of these conditions include depression, addiction, anxiety, OCD, PTSD, and eating disorders.

 

In the decades since the turn of the century public attitude has also positively shifted towards the unfettered and open-minded research of psilocybin. Now, in 2020, governing bodies are beginning to follow suit. The FDA (Federal Drug Administration) has designated psilocybin a breakthrough therapy for Major Depressive Disorder (MDD), a condition affecting over 300 million people worldwide.

 

Over a dozen accredited institutions, a few of which include Harvard, Stanford, YaleThe Usona Institute, The Heffter Institute, Johns Hopkins Universityand the University of Toronto are in the process of clinical trials/studies to determine the potential of psilocybin as a therapeutic aid, and there is a mountain of anecdotal evidence that cannot be discounted. 

Screen Shot 2019-11-16 at 6.58.32 PM.png

Some of the Universities currently studying Psilocybin.

Some of the claims made regarding psilocybin and its capability to treat a variety of conditions on a long term basis, with low frequency of dosage, may seem exaggerated or outlandish. However they are backed by a body of credible research that is constantly expanding. We have curated a collection of the most relevant studies specific to Psilocybin below.

Enzymatic Synthesis of Psilocybin
Enzymatic Synthesis of Psilocybin

Janis Fricke, Felix Blei, Dirk Hoffmeister

Potential Therapeutic Effects of Psilocybin
Potential Therapeutic Effects of Psilocybin

Matthew W. Johnson, Roland R. Griffiths

Psilocybin - Summary of Knowledge and New Perspectives
Psilocybin - Summary of Knowledge and New Perspectives

Filip Tylš, Tomáš Páleníček, Jiří Horáček

Neural correlates of ego‐dissolution under psilocybin
Neural correlates of ego‐dissolution under psilocybin

Alexander V. Lebedev, Martin Lövdén, Gidon Rosenthal, Amanda Feilding, David J. Nutt, Robin L. Carhart‐Harris

Psilocybin: Psychotherapy or drug?
Psilocybin: Psychotherapy or drug?

Guy M. Goodwin

Prediction of Psilocybin Response...
Prediction of Psilocybin Response...

Erich Studerus, Alex Gamma, Michael Kometer, Franz X. Vollenweider

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Robin L. Carhart-Harris, David Erritzoe, Tim Williams, James M. Stone, Laurence J. Reed, Alessandro Colasanti, Robin J. Tyacke, Robert Leech, Andrea L. Malizia, Kevin Murphy, Peter Hobden, John Evans, Amanda Feilding, Richard G. Wise, and David J. Nutt

Psilocybin with psychological support for treatment-resistant depression
Psilocybin with psychological support for treatment-resistant depression

R. L. Carhart-Harris, M. Bolstridge, C. M. J. Day, J. Rucker, R. Watts, D. E. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, H. V. Curran & D. J. Nutt

Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects
Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects

Michael Kometer, André Schmidt, Lutz Jäncke, and Franz X. Vollenweider